Bcl-x

Bcl-x Molekülinformation

Englischer Name	Apoptosis regulator Bcl-X	Anzahl der inverkehr gebrachten Arzneimittel	1
Anzahl der klinischen Arzneimittel	8	Target-Alias	Bcl-2-like protein 1，Bcl2-L-1，BCL2L，Apoptosis regulator Bcl-X，BCL2L1，BCL2 Like 1，Protein Phosphatase 1， Regulatory Subunit 52，BCLX，BCL-XL/S，PPP1R52，Bcl-X，bcl-X Protein，Bcl-XL，Bcl-XS
Höchste Forschungs- und Entwicklungsphase	Approved

Englischer Name	Apoptosis regulator Bcl-X
Target-Alias	Bcl-2-like protein 1，Bcl2-L-1，BCL2L，Apoptosis regulator Bcl-X，BCL2L1，BCL2 Like 1，Protein Phosphatase 1， Regulatory Subunit 52，BCLX，BCL-XL/S，PPP1R52，Bcl-X，bcl-X Protein，Bcl-XL，Bcl-XS
Anzahl der inverkehr gebrachten Arzneimittel	1
Anzahl der klinischen Arzneimittel	8
Höchste Forschungs- und Entwicklungsphase	Approved

Bcl-x Produktliste

Attribut
Protein (2)
Produktbibliothek
Online (2)
Spezies
Human (2)
Etikett
His Tag (1)GST Tag (1)
Marker
Unconjugated (2)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
BC1-H5120	Human	E. coli	Human Bcl-x / BCL2L1 Protein, His Tag				In den Warenkorb legen
BC1-H513a	Human	E. coli	Human Bcl-x / BCL2L1 Protein, GST Tag				In den Warenkorb legen

Gesamtmenge2

Bcl-x Molekülhintergrund

Bcl-2-like protein 1 (BCL2L1), is also known as Apoptosis regulator Bcl-X (Bcl-XL). BCL2L1 / Bcl-XL is a homodimer protein and belongs to the Bcl-2 family. BCL2L1 is expressed at high levels in cells that undergo a high rate of turnover, such as developing lymphocytes. BCL2L1 is a potent inhibitor of cell death. BCL2L1 Inhibits activation of caspases. BCL2L1 appears to regulate cell death by blocking the voltage-dependent anion channel (VDAC) by binding to it and preventing the release of the caspase activator, CYC1, from the mitochondrial membrane. BCL2L1 / Bcl-XL also acts as a regulator of G2 checkpoint and progression to cytokinesis during mitosis.

Bcl-x Molekülalias

BCL2L1,Bcl-XL,Bcl2-L-1,BCL-XL,S,BCL2L,BCLX,BCLXL,BCLXS,Bcl-X,bcl-xS

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Pelcitoclax	BM-1252; APG-1252; APG 1252 12A	Phase 2 Clinical	Jiangsu Ascentage Pharma Co Ltd	Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Fallopian Tube Neoplasms; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Non-Hodgkin; Neuroendocrine Tumors; Ovarian Neoplasms; Peritoneal Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Myelofibrosis; Small Cell Lung Carcinoma; Solid tumours	Details
LP-118	LP-118; NWP-0476; NWP-4-76	Phase 2 Clinical	Guangzhou Lupeng Pharmaceutical Co Ltd, Newave Pharmaceutical Inc	Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Leukemia, Prolymphocytic, T-Cell; Lymphoma, Non-Hodgkin; Multiple Myeloma; Myelodysplastic Syndromes; Myelodysplastic-Myeloproliferative Diseases; Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Myelofibrosis; Richter's Syndrome; Solid tumours	Details
Foselutoclax	UBX-1325	Phase 2 Clinical	Ascentage Pharma Group International	Diabetic macular oedema; Macular Degeneration	Details
R-(-)-gossypol acetic acid	R-(-) BL-193; AT-101; NSC-726190	Phase 2 Clinical	Jiangsu Ascentage Pharma Co Ltd, University Of Michigan	Adrenocortical Carcinoma; Brain Neoplasms; Burkitt Lymphoma; Carcinoma, Non-Small-Cell Lung; CNS Embryonal Tumor; Esophageal Neoplasms; Glioblastoma; Gliosarcoma; Hormone-Resistant Prostate Neoplasms; Laryngeal Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Lymphoma; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Peripheral; Lymphomatoid Granulomatosis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Waldenstrom Macroglobulinemia	Details
Mirzotamab clezutoclax	ABBV-155	Phase 1 Clinical	Abbvie Inc	Solid tumours	Details
TQB-3142	TQB-3142	Phase 1 Clinical	Sino Biopharmaceutical Ltd	Neoplasms	Details
DT-2216	DT-2216	Phase 1 Clinical	The University Of Texas MD Anderson Cancer Center, University Of Florida, UT Health San Antonio	Hematologic Neoplasms; Solid tumours	Details
ABBV-637	ABBV-637	Phase 1 Clinical	Abbvie Inc	Carcinoma, Non-Small-Cell Lung; Solid tumours	Details

Inverkehr gebrachte Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Frühestes Markenname	Frühestes Genehmigungsland	Früheste Indikation	Früheste Genehmigungsgesellschaft	Früheste Genehmigungsdatum	Indikationen	Klinische Studie
Gossypol acetic acid/Potassium Chloride/Vitamin B1/Vitamin B6		Approved	Xi'An Beifang Medicine Co Ltd		Mainland China	Uterine Hemorrhage; Uterine Neoplasms; Endometriosis	Xi'An Beifang Medicine Co Ltd	1988-01-01	Endometriosis; Uterine Hemorrhage; Uterine Neoplasms	Details